Fosmidomycin

Structural formula
General
Non-proprietary name	Fosmidomycin
other names	[3- ( N -hydroxyformamido) propyl] phosphonic acid
Molecular formula	C 4 H 10 NO 5 P
External identifiers / databases
PubChem	572
DrugBank	DB02948
Wikidata	Q905038
Drug information
Drug class	antibiotic
properties
Molar mass	183.10 g mol −1
safety instructions
GHS hazard labeling ; no classification available
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Fosmidomycin is an antibiotic from Streptomyces lavendulae , a type of streptomycete .

It inhibits the methylerythritol phosphate pathway , which leads to the biosynthesis of the terpene building blocks isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP). This can be found z. B. in Plasmodium falciparum , the causative agent of malaria .

The basic building blocks IPP and DMAPP are involved in the formation of hormones, cholesterol, cell membranes and protein structures. If these are missing, the malaria pathogen must die. The enzyme that is inhibited by fosmidomycin is deoxy- D -xylulose-5-phosphate reductase.

Individual evidence

↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ S Borrmann, et al. : Fosmidomycin-clindamycin for Plasmodium falciparum infections in African children . In: J Infect Dis . 189, No. 5, 2004, pp. 901-908. doi : 10.1086 / 381785 .
↑ S Borrmann, et al. : Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria . In: Antimicrob Agents Chemother . 50, No. 8, 2006, pp. 2713-2718. doi : 10.1128 / AAC.00392-06 .
↑ R Ruangweerayut, et al. : Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria . In: Malaria J . 7, 2008, p. 225. doi : 10.1186 / 1475-2875-7-225 .

[NV-1] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[Borrmann2004-2] S Borrmann, et al. : Fosmidomycin-clindamycin for Plasmodium falciparum infections in African children . In: J Infect Dis . 189, No. 5, 2004, pp. 901-908. doi : 10.1086 / 381785 .

[Borrmann2006-3] S Borrmann, et al. : Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria . In: Antimicrob Agents Chemother . 50, No. 8, 2006, pp. 2713-2718. doi : 10.1128 / AAC.00392-06 .

[Ruangweerayut2008-4] R Ruangweerayut, et al. : Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria . In: Malaria J . 7, 2008, p. 225. doi : 10.1186 / 1475-2875-7-225 .